It was also observed that CD44 isoforms v3, v6, and v10 were significantly associated with advanced primary tumour stage, metastasis, treatment failure, and reduced disease-free survival, indicating that CD44 is a useful marker for HNSCC progression and a possible target for therapy [75]. Here, CD44 is linked to neoplasm.